Endocrine Oncology, Pituitary Disorders
Temozolomide in the Treatment of Aggressive Pituitary Tumours – An Overview of Existing Knowledge and Future Perspectives
Ann McCormack
Pituitary tumours are common, with an estimated prevalence of 16.7 % in the general population based on imaging and autopsy studies.1 Clinically significant pituitary tumours are more prevalent than previously recognised, with one case per 1,000–1,300 people.2,3 The majority of pituitary tumours are indolent, slow-growing neoplasms. However, 40–50 % of pituitary tumours are locally invasive […]